Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: Results of the DESSOLVE II trial

EuroIntervention

Volumn 10, Issue 12, 2015, Pages 1383-1390

  Wijns, William ^a   Vrolix, Mathias ^b   Verheye, Stefan ^c   Schoors, Danny ^d   Slagboom, Ton ^e   Gosselink, Marcel ^f   Benit, Edouard ^g   Donohoe, Dennis ^h   Knape, Charlene ^h   Attizzani, Guilherme F ⁱ   Lansky, Alexandra J ^j   Ormiston, John ^k  

^a OLV HOSPITAL   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c ZNA Middelheim   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e OLV Hospital   (Netherlands)

^f ISALA HOSPITAL   (Netherlands)

^g Heart Center Hasselt VJZ   (Belgium)

^h Micell Technologies Inc   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Mercy Angiography Unit   (New Zealand)

more..

Author keywords

Bioabsorbable polymer; Drug eluting coronary stent; OCT; QCA; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYGLACTIN; PRASUGREL; RAPAMYCIN; ZOTAROLIMUS; ANTINEOPLASTIC ANTIBIOTIC; POLYMER;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY STENOSIS; MIDDLE AGED; NEOINTIMA; PATHOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; RADIOGRAPHY; RESTENOSIS; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; SINGLE-BLIND METHOD; SIROLIMUS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84928394234     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY14M05_03     Document Type: Article

References (29)

1. Nebeker JR, Virmani R, Bennett C.L., Hoffman JM, Samore MH, Alvarez J, Davidson C.J., McKoy JM, Raisch DW, Whisenant BK, Yarnold P.R., Belknap SM, West DP, Gage JE, Morse R.E., Gligoric G., Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47:175-81.
2. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115:1440-5.
3. Mauri L, Orav EJ, O'Malley AJ, Moses JW, Leon M.B., Holmes DR Jr, Teirstein PS, Schofer J, Breithardt G, Cutlip D.E., Kereiakes DJ, Shi C, Firth BG, Donohoe D.J., Kuntz RE. Relationship of late loss in lumen diameter to coronary restenosis in sirolimuseluting stents. Circulation. 2005; 111:321-7.
4. Cutlip DE, Windecker S, Mehran R., Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P., McFadden E, Lansky A, Hamon M., Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344-51.
5. Carlyle WC, McClain JB, Tzafriri A.R., Bailey L., Zani BG, Markham PM, Stanley JR, Edelman ER Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. J Control Release. 2012; 162:561-7.
6. Meredith IT, Ormiston J, Whitbourn R., Kay IP, Muller D, Bonan R, Popma J.J., Cutlip DE, Fitzgerald P, Prpic R, Kuntz RE First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary lesions: Endeavor I Trial. Euro Intervention. 2005; 1:157-64.
7. Gershlick A, Kandzari DE, Leon M.B., Wijns W., Meredith IT, Fajadet J, Popma JJ, Fitzgerald P.J., Kuntz RE; ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol. 2007; 100:45M-55M.
8. Ormiston J, Webster M, Stewart J., Vrolix M, Whitbourn R, Donohoe D., Knape C, Lansky A, Attizzani G.F., Fitzgerald P., Kandzari DE, Wijns W. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). JACC Cardiovasc Interv. 2013; 6:1026-34.
9. Bezerra HG, Costa MA, Guagliumi G, Rollins A.M., Simon DI. Intracoronary optical coherence tomography: a comprehensive review. JACC Cardiovasc Interv. 2009; 2:1035-46.
10. Attizzani GF, Bezerra HG, Chamié D, Fujino Y, Spognardi AM, Stanley JR, Yamamoto H, Mehanna E, Wang W, Carlyle WC, McClain JB, Costa MA. Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT): an optical coherence tomography and histopathological study. J Invasive Cardiol. 2012; 24:560-8.
11. Attizzani GF, Bezerra HG, Ormiston J, Wang W., Donohoe D, Wijns W, Costa MA Serial assessment by optical coherence tomography of early and late vascular responses after implantation of an absorbable-coating Sirolimus-Eluting stent (from the first-inhuman DESSOLVE I trial). Am J Cardiol. 2013; 112:1557-64.
12. Mehanna EA, Attizzani GF, Kyono H, Hake M., Bezerra HG. Assessment of coronary stent by optical coherence tomography, methodology and definitions. Int J Cardiovasc Imaging. 2011; 27: 259-69.
13. Gonzalo N, Garcia-Garcia HM, Serruys P.W., Commissaris KH, Bezerra H, Gobbens P, Costa M., Regar E. Reproducibility of quantitative optical coherence tomography for stent analysis. Euro Intervention. 2009; 5:224-32.
14. Kume T, Akasaka T, Kawamoto T., Ogasawara Y, Watanabe N, Toyota E., Neishi Y, Sukmawan R, Sadahira Y., Yoshida K. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol. 2006; 97:1713-7.
15. Kume T, Okura H, Kawamoto T., Akasaka T, Toyota E, Watanabe N., Neishi Y, Sadahira Y, Yoshida K. Images in cardiovascular medicine. Fibrin clot visualized by optical coherence tomography. Circulation. 2008; 118:426-7.
16. Park SJ, Kang SJ, Virmani R, Nakano M., Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012; 59:2051-7.
17. Kandzari DE, Leon MB, Meredith I, Fajadet J., Wijns W, Mauri L. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC Cardiovasc Interv. 2013; 6:504-12.
18. Maeng M, Tilsted HH, Jensen L.O., Kaltoft A., Kelbæk H, Abildgaard U., Villadsen AB, Krusell LR, Ravkilde J, Hansen K.N., Christiansen EH, Aarøe J, Jensen J.S., Kristensen SD, Bøtker HE, Madsen M, Thayssen P, Sørensen HT, Thuesen L, Lassen JF. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv. 2012; 5:812-8.
19. Ellis SG, Popma JJ, Lasala J.M., Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R., Bergin P, Greenberg J, Stone GW Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005; 45:1193-200.
20. Cassese S, Ndrepepa G, King L.A., Tada T., Fusaro M, Kastrati A. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. Heart. 2012; 98:1632-40.
21. Maeng M, Jensen LO, Tilsted H.H., Kaltoft A., Kelbaek H, Abildgaard U, Villadsen A., Aarøe J, Thayssen P., Krusell LR, Christiansen EH, Bøtker HE, Kristensen SD, Ravkilde J, Madsen M, Sørensen HT, Rasmussen K, Thuesen L, Lassen JF. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am J Cardiol. 2011; 108:1232-7.
22. Hannan EL, Zhong Y, Wu C., Walford G, Holmes DR Jr, Jacobs AK, Stamato NJ, Venditti FJ, Sharma S, Fergus I., King SB 3rd. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State. Catheter Cardiovasc Interv. 2013; 81:1097-105.
23. Bangalore S, Toklu B, Amoroso N., Fusaro M, Kumar S, Hannan E.L., Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison metaanalysis. BMJ. 2013; 347:f6625.
24. Hamilos M, Sarma J, Ostojic M., Cuisset T, Sarno G, Melikian N., Ntalianis A, Muller O, Barbato E., Beleslin B, Sagic D, De Bruyne B, Bartunek J, Wijns W. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv. 2008; 1:193-200.
25. Guagliumi G, Ikejima H, Sirbu V., Bezerra H, Musumeci G, Lortkipanidze N., Fiocca L, Tahara S, Vassileva A., Matiashvili A, Valsecchi O, Costa M. Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions). JACC Cardiovasc Interv. 2011; 4:778-85.
26. Guagliumi G, Bezerra HG, Sirbu V, Ikejima H., Musumeci G, Biondi-Zoccai G, Lortkipanidze N, Fiocca L., Capodanno D, Wang W, Tahara S., Vassileva A, Matiashvili A, Valsecchi O., Costa MA. Serial assessment of coronary artery response to paclitaxel-eluting stents using optical coherence tomography. Circ Cardiovasc Interv. 2012; 5:30-8.
27. Guagliumi G, Capodanno D, Ikejima H., Bezerra HG, Sirbu V, Musumeci G, Fiocca L., Lortkipanidze N, Vassileva A, Tahara S., Valsecchi O, Costa MA. Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST. Catheter Cardiovasc Interv. 2013; 81:510-8.
28. Guagliumi G1, Sirbu V, Musumeci G, Gerber R, BiondiZoccai G, Ikejima H, Ladich E, Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, Stone GW. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv. 2012; 5:12-20.
29. Attizzani GF, Capodanno D, Ohno Y., Tamburino C. Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition. J Am Coll Cardiol. 2014; 63:1355-67. Online data supplement Online Appendix A. Investigators and institutions that participated in DESSOLVE II. Online Appendix B. Main study exclusion criteria.